Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07465276 · ClinicalTrials.gov registry record · Phase 2
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
A Phase 2 study, sponsored by Dana-Farber Cancer Institute.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT07465276 is a Phase 2 study that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 32 participants.
The verdict
NCT07465276, a Phase 2 study, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs used in this research study are: * ficerafusp alfa (a type of bifunctional antibody and recombinant fusion protein) * pembrolizumab (a type of monoclonal antibody)
Interventions
- DRUG Pembrolizumab
- DRUG Ficerafusp alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2026-03-26 |
| Est. Completion | 2030-04-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07465276
The ClinicalTrials.gov registry entry for NCT07465276 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT07465276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07465276 about?
NCT07465276 is a clinical study titled "Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC". This trial is to evaluate the safety and efficacy of ficerafusp alfa in combination with pembrolizumab prior to surgical resection in participants with resectable, high-risk, locoregionally advanced, PD-L1-positive squamous cell carcinoma of the head and neck (HNSCC). The names of the study drugs u...
What is the current status of trial NCT07465276?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2026-03-26. Estimated completion is 2030-04-30.
What interventions are being tested in trial NCT07465276?
The interventions under investigation include: Pembrolizumab (DRUG), Ficerafusp alfa (DRUG).
Who is sponsoring clinical trial NCT07465276?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.